McKesson (NYSE:MCK) Announces FY 2027 Earnings Guidance

McKesson (NYSE:MCK) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share guidance of 44.200-45.000 for the period, compared to the consensus EPS estimate of 44.650. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of analysts recently issued reports on MCK shares. Morgan Stanley restated an “overweight” rating on shares of McKesson in a research report on Friday, August 7th. Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Evercore restated an “outperform” rating on shares of McKesson in a report on Thursday, August 6th. UBS Group lifted their price target on shares of McKesson from $1,050.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, September 4th. Fourteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $973.44.

McKesson Stock Down 1.0%

Shares of NYSE MCK opened at $856.46 on Thursday. The business has a fifty day simple moving average of $877.23 and a two-hundred day simple moving average of $833.40. The firm has a market cap of $99.86 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 1.72 and a beta of 0.30. McKesson has a twelve month low of $723.68 and a twelve month high of $999.00.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping the consensus estimate of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The business had revenue of $105.38 billion during the quarter, compared to analysts’ expectations of $103.88 billion. During the same period in the prior year, the business earned $8.26 EPS. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, research analysts expect that McKesson will post 44.64 earnings per share for the current year.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. This is a boost from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date of this dividend is Tuesday, September 1st. McKesson’s payout ratio is currently 10.06%.

Insiders Place Their Bets

In other news, CEO Brian S. Tyler sold 8,463 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total value of $6,715,898.28. Following the completion of the sale, the chief executive officer owned 5,919 shares of the company’s stock, valued at approximately $4,697,081.64. This represents a 58.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley E. Lerman sold 301 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 8,875 shares of company stock worth $7,083,441 in the last three months. Corporate insiders own 0.06% of the company’s stock.

About McKesson

McKesson Corporation (NYSE:MCK) is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson’s principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.